Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs

International Journal of Neuropsychopharmacology

Volumn 15, Issue 8, 2012, Pages 1149-1160

  Pereira, Avril ^a,b   Sugiharto Winarno, Anthony ^a   Zhang, Betty ^a   Malcolm, Peter ^a   Fink, George ^a,b   Sundram, Suresh ^a,b,c  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NORTHERN HOSPITAL   (Australia)

Author keywords

Antipsychotic drug; clozapine; EGF receptor; ERK; schizophrenia

Indexed keywords

CLOZAPINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE 1; OLANZAPINE; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENZYME PHOSPHORYLATION; IN VIVO STUDY; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PREFRONTAL CORTEX; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TYROSINE;

EID: 84864538870     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001404     Document Type: Article

References (45)

1. Ahmed MR, Gurevich VV, Dalby KN, Benovic JL, et al. (2008). Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. Journal of Pharmacology and Experimental Therapeutics 325, 276-283.
2. Bespalov A, Jongen-Relo AL, van Gaalen M, Harich S, et al. (2007). Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. Journal of Pharmacology and Experimental Therapeutics 320, 944-950.
3. Britsch S (2007). The neuregulin-I/ErbB signaling system in development and disease. Advances in Anatomy, Embryology and Cell Biology 190, 1-65.
4. Browning JL, Patel T, Brandt PC, Young KA, et al. (2005). Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biological Psychiatry 57, 617-623.
5. Buxbaum JD, Georgieva L, Young JJ, Plescia C, et al. (2008). Molecular dissection of NRG1-ERBB4 signalling implicates PTPRZ1 as a potential schizophrenia susceptibility gene. Molecular Psychiatry 13, 162-172.
6. Cussac D, Duqueyroix D, Newman-Tancredi A, Millan MJ (2002). Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors. Psychopharmacology (Berlin) 162, 168-177.
7. Ellis AG, Doherty MM, Walker F, Weinstock J, et al. (2006). Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochemical Pharmacology 71, 1422-1434.
8. Engel SR, Creson TK, Hao Y, Shen Y, et al. (2009). The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Molecular Psychiatry 14, 448-461.
9. Fumagalli F, Frasca A, Sparta M, Drago F, et al. (2006). Long-term exposure to the atypical antipsychotic olanzapine differently up-regulates extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular compartments of rat prefrontal cortex. Molecular Pharmacology 69, 1366-1372.
10. Futamura T, Kakita A, Tohmi M, Sotoyama H, et al. (2003). Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: implication for epidermal growth factor in cognitive development. Molecular Psychiatry 8, 19-29.
11. Futamura T, Toyooka K, Iritani S, Niizato K, et al. (2002). Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Molecular Psychiatry 7, 673-682.
12. Girgenti MJ, Nisenbaum LK, Bymaster F, Terwilliger R, et al. (2010). Antipsychotic-induced gene regulation in multiple brain regions. Journal of Neurochemistry 113, 175-187.
13. Hanninen K, Katila H, Anttila S, Rontu R, et al. (2007). Epidermal growth factor A61G polymorphism is associated with the age of onset of schizophrenia in male patients. Journal of Psychiatric Research 41, 8-14.
14. Harrison PJ, Weinberger DR (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry 10, 40-68.
15. Ichikawa JJ, Dai J, O'Laughlin IA, Fowler WL, et al. (2002). Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26, 325-339.
16. Ikeda YN, Yahata N, Ito I, Nagano M, et al. (2008). Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophrenia Research 101, 58-66.
17. Kamei H, Nagai T, Nakano H, Togan Y, et al. (2006). Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biological Psychiatry 59, 75-84.
18. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. American Journal of Psychiatry 158, 360-369.
19. Kato T, Abe Y, Sotoyama H, Kakita A, et al. (2011). Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Molecular Psychiatry 16, 307-320.
20. Kim SH, Seo MS, Jeon WJ, Yu HS, et al. (2008). Haloperidol regulates the phosphorylation level of the MEK-ERK-p90RSK signal pathway via protein phosphatase 2A in the rat frontal cortex. International Journal of Neuropsychopharmacology 11, 509-517.
21. Konradi C, Heckers S (2001). Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biological Psychiatry 50, 729-742.
22. Kuroki T, Meltzer HY, Ichikawa J (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 288, 774-781.
23. Leucht S, Corves C, Arbter D, Engel RR, et al. (2009). Second-generation vs. first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41.
24. Lewis SW, Barnes TR, Davies L, Murray RM, et al. (2006). Randomized controlled trial of effect of prescription of clozapine vs. other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32, 715-723.
25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
26. Lu XH, Bradley RJ, Dwyer DS (2004). Olanzapine produces trophic effects in vitro and stimulates phosphorylation of akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Research 1011, 58-68.
27. Lu XH, Dwyer DS (2005). Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. Journal of Molecular Neuroscience 27, 43-64.
28. Masri B, Salahpour A, Didriksen M, Ghisi V, et al. (2008). Antagonism of dopamine d2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proceedings of the National Academy of Sciences USA 105, 13656-13661.
29. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, et al. (2006). Effectiveness of clozapine vs. olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163, 600-610.
30. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10, 79-104.
31. Pantelis C, Lambert TJ (2003). Managing patients with 'treatment-resistant' schizophrenia. Medical Journal of Australia 178 (Suppl.), S62-S66.
32. Pereira A, Fink G, Sundram S (2009). Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor. Journal of Molecular Neuroscience 39, 185-198.
33. Pozzi L, Hakansson K, Usiello A, Borgkvist A, et al. (2003). Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and elk-1 phosphorylation in mouse dorsal striatum. Journal of Neurochemistry 86, 451-459.
34. Prenzel N, Zwick E, Daub H, Leserer M, et al. (1999). EGF receptor transactivation by g-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884-888.
35. Seeman P (2002). Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 47, 27-38.
36. Sotoyama H, Namba H, Takei N, Nawa H (2007). Neonatal exposure to epidermal growth factor induces dopamine D2-like receptor supersensitivity in adult sensorimotor gating. Psychopharmacology (Berlin) 191, 783-792.
37. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics 71, 877-892.
38. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, et al. (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 163, 611-622.
39. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, et al. (2008). World psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research 100, 20-38.
40. Valjent E, Pages C, Herve D, Girault JA, et al. (2004). Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain. European Journal of Neuroscience 19, 1826-1836.
41. Valjent E, Pascoli V, Svenningsson P, Paul S, et al. (2005). Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proceedings of the National Academy of Sciences USA 102, 491-496.
42. Wetzker R, Bohmer FD (2003). Transactivation joins multiple tracks to the ERK/MAPK cascade. Nature Reviews Molecular Cell Biology 4, 651-657.
43. Wong RW, Guillaud L (2004). The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine and Growth Factor Reviews 15, 147-156.
44. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology 8, 457-472.
45. Yang BH, Son H, Kim SH, Nam JH, et al. (2004). Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration. Psychiatry Clinical Neuroscience 58, 262-267.